跳至主要内容
临床试验/IRCT2014040617150N1
IRCT2014040617150N1已完成未知

Placebo-controlled clinical trial to determine the effects of dietary zinc supplementation on serum levels of brain-derived neurotrophic factor, vascular endothelial growth factor, advanced glycation end products, metalloproteinas 9 and caspase 3 in patients with diabetic retinopathy

Vice chancellor for Research, Tabriz University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
40 years 至 70 years(—)
性别
All

入选标准

  • Age range 40-70 years old
  • suffering from type 2 diabetes without insulin
  • Subject diagnosed with diabetic retinopathy

排除标准

  • Insulin injection
  • Having chronic diseases such as cardiovascular disorders, renal and hepatic
  • Having malabsorption syndrome and inflammatory bowel disease.
  • Pregnancy and lactation
  • Drugs interfering with zinc (Penicillin amine, Diethylenetriamine pentaacetate)
  • ; Inhibitor drugs vascular endothelial growth factor (Avastin)
  • Receiving nutritional supplements from 2 months before the study (zinc, calcium, vitamin A and iron)
  • Exercise on a regular basis
  • Having a mental illness such as depression
  • Infectious diseases and AIDS

研究者

发起方
Vice chancellor for Research, Tabriz University of Medical Sciences

相似试验